Biotechnology

Viking Therap

Viking Therap released FY2026 Q1 earnings on April 29 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -1.37 (forecast USD -0.9952)

Viking Therap to Release FY2026 Q1 Earnings on April 29 After-Market EST, Forecast EPS USD -1.0302

Viking Therap released FY2025 Q4 earnings on February 11 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -0.9068)

Viking Therapeutics released FY2025 Annual Earnings on February 11 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.192 (forecast USD -2.7218)

Viking Therap to Release FY2025 Q4 Earnings on February 11 After-Market (EST), Forecast EPS: USD -0.9055

William Blair Maintains Viking Therapeutics 'VKTX' Buy Rating

Viking Therapeutics Completes VK2735 Obesity Maintenance Dose Study Patient Recruitment

Voya 大幅减持 Viking 股票

U.S. Capital Wealth Advisors LLC Increased Holdings in Viking Therapeutics Inc.

H.C. Wainwright Analyst Reiterates Buy Rating on Viking Therapeutics

Viking Therapeutics Inc. Updates Clinical Pipeline, Emphasizes Progress in Metabolic and Endocrine Disease Programs

Scotia Capital Acquires Shares of Viking Therapeutics

Rockefeller Capital Management Increases Holdings in Viking Therapeutics, Inc.

Zacks Research Raises Viking Therapeutics' Rating to Hold

Viking Therapeutics Completes Enrollment in VK2735 Phase III Clinical Trial

William Blair and Canaccord Genuity Maintain Buy Rating on Viking Therapeutics Stock

Persistent Asset Partners Ltd increased holdings of Viking Therapeutics, Inc. in Q2

VK2735 Phase III Clinical Trial Results Presented at AHA's Scientific Sessions

Roberts Glore Boosts Viking Therapeutics Holdings in Q2

Viking Therapeutics Displays New Clinical Data for VK2735 Obesity Project

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

MetaVia

BiomX

Micware

Tradr 2X Long XNDU Daily ETF

MicroAlgo

QURE

VKTX

SBIO

LABU

Today's whale activity in health care stocks reveals significant trading opportunities. Notable options include bullish call sweeps for HIMS, NVO, VKTX, and ELV, with varying expiration dates and strike prices. REPL shows a bullish put trade, while QURE has a bearish call trade. The data indicates abnormal trading volumes, suggesting potential market movements. Traders are advised to monitor these activities closely for investment strategies.

benzinga_article

Uniqure

Novo Nordisk AS

ALPS Medical Breakthrough

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Defiance Leveraged Long +Income HIMS ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

SPDR S&P Health

VG Health

iShares US Medical Devices

SPDR S&P Health Equip

VanEck Biotech ETF

Defiance Daily Target 2X Long NVO ETF

First Trust NYSE Arca Biotech Index Fd

Defiance Daily Target 2X Long HIMS ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Hims & Hers Health

Replimune

Zoetis

Elevance Health

Intuitive Surgical

Centene

CVS Health

10 Health Care Stocks Whale Activity In Today's Session

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 | VKTX Stock News

StockTitan

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 | VKTX Stock News

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 | VKTX Stock News

iShares Biotechnology ETF

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 | VKTX Stock News

ARKG

Analyst Edward Nash from Canaccord Genuity has maintained a Buy rating on Viking Therapeutics with a price target of $107. Despite a larger-than-expected quarterly loss due to high R&D spending, the company has over $600M in cash, ensuring operations are funded into 2028. Nash highlights the expansion of the VK2735 study as a key value driver. BTIG also reiterated a Buy rating with a $125 price target.

Tip Ranks

Ark Genomic Revolution ETF

Nash Maintains Buy on Viking Therapeutics, Keeps $107 Price Target Unchanged Amid Strong Cash Runway and Expanded VK2735 Study

BTIG Research has reaffirmed a "buy" rating for Viking Therapeutics (VKTX) with a target price of $125.00, indicating a potential upside of 316.67% from its current price. Other analysts have varied opinions, with Cantor Fitzgerald lowering their target to $100.00 and HC Wainwright maintaining a buy rating at $102.00. The stock opened at $30.00, with a market cap of $3.48 billion. Viking reported a quarterly EPS of ($1.37), missing estimates. Institutional investors hold 76.03% of the stock, reflecting strong interest in the company.

Market Beat

Morgan Stanley

Nasdaq

Ameriprise Financial

BNP Paribas

Raymond James Financial

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Viking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at BTIG Research

Stifel Nicolaus analyst Annabel Samimy has maintained a Buy rating on Viking Therapeutics (VKTX) with a price target of $95.00. The analyst consensus for VKTX is a Strong Buy, with an average price target of $93.27. Samimy has an average return of 16.0% and a 50.00% success rate on her stock recommendations, focusing on the Healthcare sector.

Viking Therap(VKTX.US)

10 Health Care Stocks Whale Activity In Today's Session

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 | VKTX Stock News

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 | VKTX Stock News

Nash Maintains Buy on Viking Therapeutics, Keeps $107 Price Target Unchanged Amid Strong Cash Runway and Expanded VK2735 Study

Viking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at BTIG Research

Stifel Nicolaus Remains a Buy on Viking Therapeutics (VKTX)

Viking Therap | 10-Q: FY2026 Q1 Revenue: USD 0